Comparison of 12-Month Courses of Interferon- -2b-Lamivudine Combination Therapy and Interferon- -2b Monotherapy among Patients with Untreated Chronic Hepatitis B
- 15 June 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (12), 1516-1522
- https://doi.org/10.1086/375085
Abstract
We compared the use of prolonged synchronous combination therapy with interferon (IFN)-α-2b and lamivudine with the use of IFN-α-2b monotherapy in patients with untreated hepatitis B e antigen (HBeAg)–positive chronic hepatitis B virus (HBV) infection. Thirty-three patients received therapy with lamivudine (100 mg daily) and IFN-α-2b (10 million U 3 times per week) for 12 months; 16 patients received IFN-α-2b alone (10 million U 3 times per week for 12 months). The primary end point was sustained suppression of HBV DNA and HBeAg seroconversion, which was observed in 15 (45%) of 33 patients treated with combination therapy and in 3 (19%) of 16 patients treated with monotherapy (P = .133). Both therapeutic regimens were well tolerated. Combination therapy increased the rate of sustained suppression of HBeAg and resulted in significant improvement in Knodell histologic activity index scores, compared with monotherapy. However, there was no significant difference in rates of sustained suppression between the 2 groups at the end of follow-up.Keywords
This publication has 19 references indexed in Scilit:
- Combined Interferon and Lamivudine Therapy: Is This The Treatment of Choice for Patients With Chronic Hepatitis B Virus Infection?Hepatology, 2003
- Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trialGut, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatmentHepatology, 1999
- Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.JCI Insight, 1998
- A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serumHepatology, 1997
- Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis BJournal of Hepatology, 1996
- Hepatitis B Virus ImmunopathogenesisAnnual Review of Immunology, 1995
- Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factorsHepatology, 1989
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisHepatology, 1981